1. molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history.
- Author
-
Usyk, Mykhaylo, Schlecht, Nicolas, Pickering, Sarah, Williams, LaShanda, Sollecito, Christopher, Gradissimo, Ana, Porras, Carolina, Safaeian, Mahboobeh, Pinto, Ligia, Herrero, Rolando, Strickler, Howard, Viswanathan, Shankar, Nucci-Sack, Anne, Diaz, Angela, and Burk, Robert
- Subjects
Adolescent ,Adult ,Alphapapillomavirus ,Bacteria ,Cytokines ,Female ,Humans ,Interleukin-1beta ,Metagenomics ,Molecular Medicine ,Neoplasms ,Papillomavirus Infections ,Risk Factors ,Vagina ,Vaginosis ,Bacterial ,Young Adult - Abstract
Bacterial vaginosis (BV) is a highly prevalent condition that is associated with adverse health outcomes. It has been proposed that BVs role as a pathogenic condition is mediated via bacteria-induced inflammation. However, the complex interplay between vaginal microbes and host immune factors has yet to be clearly elucidated. Here, we develop molBV, a 16 S rRNA gene amplicon-based classification pipeline that generates a molecular score and diagnoses BV with the same accuracy as the current gold standard method (i.e., Nugent score). Using 3 confirmatory cohorts we show that molBV is independent of the 16 S rRNA region and generalizable across populations. We use the score in a cohort without clinical BV states, but with measures of HPV infection history and immune markers, to reveal that BV-associated increases in the IL-1β/IP-10 cytokine ratio directly predicts clearance of incident high-risk HPV infection (HR = 1.86, 95% CI: 1.19-2.9). Furthermore, we identify an alternate inflammatory BV signature characterized by elevated TNF-α/MIP-1β ratio that is prospectively associated with progression of incident infections to CIN2 + (OR = 2.81, 95% CI: 1.62-5.42). Thus, BV is a heterogeneous condition that activates different arms of the immune response, which in turn are independent risk factors for HR-HPV clearance and progression. Clinical Trial registration number: The CVT trial has been registered under: NCT00128661.
- Published
- 2022